ESC 2024: Latest FLOW trial analysis highlights how Ozempic can benefit CKD patients
If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option for patients with type 2 diabetes and chronic kidney disease.
If approved, Novo Nordisk's Ozempic will become the first GLP-1 therapy option for patients with type 2 diabetes and chronic kidney disease.
What's Your Reaction?
